1017781-28-0

Basic information

• Product Name: 5-(3-FLUORO-PHENYL)-2-METHYL-2H-PYRAZOL-3-YLAMINE
• Synonyms: 5-(3-FLUORO-PHENYL)-2-METHYL-2H-PYRAZOL-3-YLAMINE;3-(3-FLUOROPHENYL)-1-METHYL-1H-PYRAZOL-5-AMINE;5-AMino-3-(3-fluorophenyl)-1-Methylpyrazole
• CAS NO: 1017781-28-0
• Molecular Formula: C10H10FN3
• Molecular Weight: 191.2
• Mol File: 1017781-28-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(3-FLUORO-PHENYL)-2-METHYL-2H-PYRAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-FLUORO-PHENYL)-2-METHYL-2H-PYRAZOL-3-YLAMINE(1017781-28-0)
• EPA Substance Registry System: 5-(3-FLUORO-PHENYL)-2-METHYL-2H-PYRAZOL-3-YLAMINE(1017781-28-0)

Safety Data

• Hazardous Substances Data: 1017781-28-0(Hazardous Substances Data)

Usage

Description

5-(3-FLUORO-PHENYL)-2-METHYL-2H-PYRAZOL-3-YLAMINE is a chemical compound that serves as a building block in the synthesis of various bicyclic heteroaryl urea, thiourea, guanidine, and cyanoguanidine compounds. These compounds act as TrkA kinase inhibitors, which have potential applications in pain treatment.

Uses

Used in Pharmaceutical Industry:
5-(3-FLUORO-PHENYL)-2-METHYL-2H-PYRAZOL-3-YLAMINE is used as a reactant in the synthetic preparation of bicyclic heteroaryl urea, thiourea, guanidine, and cyanoguanidine compounds. These compounds are TrkA kinase inhibitors, which are useful in pain treatment. By inhibiting the TrkA kinase, these compounds can potentially alleviate pain and provide therapeutic benefits for patients suffering from various types of pain conditions.

Relevant articles and documents

THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.